Penumbra Reports Positive Data for Pulmonary Embolism Treatment

Dow Jones

2025/11/04

By Katherine Hamilton

Penumbra reported positive data for a trial of its treatment for pulmonary embolism.

The use of computer-assisted vacuum thrombectomy resulted in improvements in thrombus burden reduction, heart rate, oxygen requirement and functional outcomes in patients with the blood-clot disorder, Penumbra said.

A significantly higher share of patients treated with CAVT returned to normalization within 48 hours compared to those who weren't treated with it, the Alameda, Calif., company said Monday. They had lower heart rates and were able to walk longer distances following treatment.

The results show CAVT can rapidly and safely improve patient outcomes, Chief Medical Officer James Benenati said. He said the treatment should be considered as a therapeutic option for patients with acute intermediate to high risk pulmonary embolism.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

November 03, 2025 15:26 ET (20:26 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2580247694"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580247694\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580247694?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 04:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580247694","market":"nz","top_or_hot":-1,"title":"Penumbra Reports Positive Data for Pulmonary Embolism Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Penumbra reported positive data for a trial of its treatment for pulmonary embolism. \n</p>\n<p>\n  The use of computer-assisted vacuum thrombectomy resulted in improvements in thrombus burden reduction, heart rate, oxygen requirement and functional outcomes in patients with the blood-clot disorder, Penumbra said. \n</p>\n<p>\n  A significantly higher share of patients treated with CAVT returned to normalization within 48 hours compared to those who weren't treated with it, the Alameda, Calif., company said Monday. They had lower heart rates and were able to walk longer distances following treatment. \n</p>\n<p>\n  The results show CAVT can rapidly and safely improve patient outcomes, Chief Medical Officer James Benenati said. He said the treatment should be considered as a therapeutic option for patients with acute intermediate to high risk pulmonary embolism. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 03, 2025 15:26 ET (20:26 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Penumbra Reports Positive Data for Pulmonary Embolism Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPenumbra Reports Positive Data for Pulmonary Embolism Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-04 04:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Penumbra reported positive data for a trial of its treatment for pulmonary embolism. \n</p>\n<p>\n  The use of computer-assisted vacuum thrombectomy resulted in improvements in thrombus burden reduction, heart rate, oxygen requirement and functional outcomes in patients with the blood-clot disorder, Penumbra said. \n</p>\n<p>\n  A significantly higher share of patients treated with CAVT returned to normalization within 48 hours compared to those who weren't treated with it, the Alameda, Calif., company said Monday. They had lower heart rates and were able to walk longer distances following treatment. \n</p>\n<p>\n  The results show CAVT can rapidly and safely improve patient outcomes, Chief Medical Officer James Benenati said. He said the treatment should be considered as a therapeutic option for patients with acute intermediate to high risk pulmonary embolism. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 03, 2025 15:26 ET (20:26 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2580247694","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580247694","pubTimestamp":1762201560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Penumbra reported positive data for a trial of its treatment for pulmonary embolism.The use of computer-assisted vacuum thrombectomy resulted in improvements in thrombus burden reduction, heart rate, oxygen requirement and functional outcomes in patients with the blood-clot disorder, Penumbra said.A significantly higher share of patients treated with CAVT returned to normalization within 48 hours compared to those who weren't treated with it, the Alameda, Calif., company said Monday. They had lower heart rates and were able to walk longer distances following treatment.The results show CAVT can rapidly and safely improve patient outcomes, Chief Medical Officer James Benenati said. He said the treatment should be considered as a therapeutic option for patients with acute intermediate to high risk pulmonary embolism.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","BK4082":"医疗保健设备","PEN":"Penumbra Inc"},"translate_title":"Penumbra报告肺栓塞治疗的积极数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEN":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Penumbra reported positive data for a trial of its treatment for pulmonary embolism. \n\n\n  The use of computer-assisted vacuum thrombectomy resulted in improvements in thrombus burden reduction, heart rate, oxygen requirement and functional outcomes in patients with the blood-clot disorder, Penumbra said. \n\n\n  A significantly higher share of patients treated with CAVT returned to normalization within 48 hours compared to those who weren't treated with it, the Alameda, Calif., company said Monday. They had lower heart rates and were able to walk longer distances following treatment. \n\n\n  The results show CAVT can rapidly and safely improve patient outcomes, Chief Medical Officer James Benenati said. He said the treatment should be considered as a therapeutic option for patients with acute intermediate to high risk pulmonary embolism. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 03, 2025 15:26 ET (20:26 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}